Skip to main content

Table 1 Characteristics of included studies

From: Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis

   

T category (T3,4 vs. T1,2)

 

N category (H vs. L)

 

M category (H vs. L)

 

Grade (G3 vs. G1,2)

 

DFS (death vs. survive)

 

OS 3 year (death vs. survive)

 

OS 5 year (death vs. survive)

  

N1

RR(95% CI)

N2

RR(95% CI)

N3

RR(95% CI)

N4

RR(95% CI)

N5

RR(95% CI)

N6

RR(95% CI)

N7

RR(95% CI)

Over all

 

13

1.15 (0.97, 1.35)

23

1.39 (1.07, 1.81)

4

1.79 (0.76, 4.26)

7

1.47 (1.00, 2.14)

5

1.50 (0.83, 2.71)

10

0.76 (0.59, 0.99)

12

0.76 (0.55, 1.05)

Cancer type

               

Oral

 

2

0.75 (0.48, 1.16)

9

0.82 (0.54, 1.25)

2

1.99 (0.99, 3.99)

2

0.91 (0.50, 1.67)

4

1.86 (1.47, 2.37)

3

0.85 (0.49, 1.47)

5

0.91 (0.46, 1.78)

Larynx

 

8

1.33 (1.01, 1.76)

11

2.53 (1.99, 3.21)

-

-

4

2.13 (0.99, 4.58)

-

-

5

0.87 (0.62, 1.23)

5

0.62 (0.47, 0.83)

Pharynx & Larynx

 

11

1.21 (1.08, 1.35)

14

1.95 (1.35, 2.82)

2

1.77 (0.13, 23.59)

5

1.71 (1.04, 2.79)

1

0.53 (0.29, 0.97)

7

0.72 (0.52, 0.99)

7

0.66 (0.47, 0.94)

Geographic area

               

Asia

Over all

9

1.39 (1.17, 1.64)

16

1.81 (1.26, 2.61)

3

1.82 (0.59, 5.63)

6

1.61 (1.01, 2.57)

2

0.98 (0.28, 3.4)

4

0.71 (0.56, 0.89)

4

0.8 (0.57, 1.14)

Oral

-

 

3

0.75 (0.10, 5.62)

1

2.03 (0.99, 4.17)

1

0.72 (0.02, 4.33)

1

1.87 (0.9, 3.88)

-

-

-

-

Larynx

6

1.60 (1.14, 2.25)

10

2.39 (1.65, 3.45)

-

-

4

2.13 (0.99, 4.58)

-

-

3

0.77 (0.66, 0.9)

3

0.69 (0.52, 0.91)

Larynx & pharynx

9

1.39 (1.17, 1.64)

13

1.98 (1.33, 2.95)

2

1.77 (0.13, 23.59)

5

1.71 (1.04, 2.79)

1

0.53 (0.29, 0.97)

4

0.71 (0.56, 0.89)

4

0.8 (0.57, 0.94)

Europe & USA

Over all

3

0.88 (0.76, 1.02)

6

0.90 (0.68, 1.20)

1

1.46 (0.09, 22.93)

1

1.03 (0.56, 1.92)

2

3.08 (0.74, 12.78)

6

0.78 (0.48, 1.27)

8

0.64 (0.35, 1.16)

Oral

1

0.57 (0.30, 1.11)

5

0.73 (0.52, 1.02)

1

1.46 (0.09, 22.93)

1

1.03 (0.56, 1.92)

2

3.08 (0.74, 12.78)

3

0.85 (0.49, 1.47)

5

0.90 (0.46, 1.78)

Larynx

2

0.96 (0.85, 1.08)

1

1.85 (1.07, 3.18)

-

-

-

-

-

-

2

0.96 (0.24, 3.88)

2

0.46 (0.29, 0.72)

Larynx & pharynx

2

0.96 (0.85, 1.08)

1

1.85 (1.07, 3.18)

-

-

-

-

-

-

3

0.61 (0.15, 2.5)

3

0.36(0.23, 0.57)

Oral

Pan-CD44

2

0.75 (0.48, 1.16)

3

0.58 (0.37, 0.92)

2

1.99 (0.99, 3.99)

2

0.91 (0.5, 1.67)

2

1.65 (1.68, 2.13)

3

0.85 (0.49, 1.47)

4

0.69 (0.32, 1.52)

 

CD44-6

-

-

2

0.79 (0.29, 2.12)

-

-

-

-

-

-

-

-

-

-

Larynx

Pan-CD44

5

1.25 (0.90, 1.73)

6

2.83 (2.01, 3.98)

2

-

4

2.13 (0.99, 4.58)

-

-

5

0.87 (0.62, 1.23)

3

0.66 (0.46, 0.95)

 

CD44-6

2

1.34 (0.99, 1.82)

4

1.92 (1.39, 2.64)

-

-

-

-

-

-

-

-

2

0.53 (0.37, 0.77)

Larynx & pharynx

Pan-CD44

6

1.23 (0.92, 1.65)

7

2.74 (1.98, 3.81)

1

6.65 (0.93, 47.63)

4

2.13 (0.99, 4.58)

1

0.53 (0.29, 0.97)

6

0.794 (0.56, 1.1)

4

0.56 (0.34, 0.93)

 

CD44-6

3

1.15 (0.90, 1.48)

5

1.47 (0.90, 2.42)

1

1.03 (0.94, 1.13)

-

-

-

-

-

-

2

0.53 (0.37, 0.77)

Sample size a

<58.5

4

1.79 (0.82, 3.89)

10

1.388 (0.83, 2.33)

1

6.65 (0.93, 47.63)

3

1.34 (0.5, 3.58)

3

1.71 (0.44, 6.69)

3

0.34 (0.21, 0.54)

6

0.55 (0.22, 1.37)

 

≥58.5

9

1.03 (0.91, 1.17)

13

1.40 (1.01, 1.95)

3

1.62 (0.87, 3.03)

4

1.62 (0.91, 2.88)

2

1.65 (1.28, 2.13)

7

0.91 (0.69, 1.2)

6

0.80 (0.57, 1.13)

Follow time(month) b

<68.5

7

1.04 (0.89, 1.20)

8

1.29 (0.80, 2.10)

2

4.51 (0.96, 21.13)

5

1.42 (0.96, 2.08)

5

1.50 (0.83, 2.71)

7

0.88 (0.66, 1.17)

8

0.89 (0.62, 1.28)

 

≥68.5

6

1.37 (0.94, 2.01)

15

1.45 (1.03, 2.05)

2

1.28 (0.36, 4.50)

2

1.27 (0.11,14.01)

-

-

3

0.39 (0.25, 0.62)

4

0.43 (0.29, 0.65)

  1. a: median of sample size for each study.
  2. b: median of follow-up time for each study.
  3. H: high expression; L: low expression; DFS: disease free survival; OS: overall survival.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us